// COMPANY
Apogee Therapeutics
// OVERVIEW
Nasdaq-listed biopharma company that received up to $1.3B in nondilutive funding from Blackstone Life Sciences.
Discussed in
// RECENT MENTIONS
// SIGNALS
4 SIGNALS
01
m_and_a·PitchBook News·JUNE 23, 2026
“AbbVie agreed to buy biotech Apogee Therapeutics, which develops treatments for atopic dermatitis and other inflammatory diseases, in a $10.9 billion deal.”
Source→02
m_and_a·Axios Pro Rata·JUNE 22, 2026
“AbbVie... Agreed to acquire Apogee Therapeutics for $10.9B in cash”
AI-extracted from podcast / newsletter / paper summaries. May contain errors.